Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis

Overview

This study is a cross sectional study of patients diagnosed with clinically isolated syndrome (CIS) and RRMS, who will undergo a series of tests to assess cognitive impairment, fatigue severity and depressive symptoms. Cognitive impairment will be assessed with Multiple Sclerosis Inventory Cognition (MUSIC) and symbol digit modalities test (SDMT), fatigue severity will be measured with the Fatigue Scale for Motor and Cognitive Functions (FSMC) and depressive symptoms with the Beck Depression Inventory (BDI). All tests mentioned above are validated for MS patients. In the second step we will use our large longitudinal database of serial MRI examinations from which a linear measurement of CCI will be retrospectively calculated.

Full Title of Study: “Cohort Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Early and Remitting Relapsing Multiple Sclerosis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 2011

Arms, Groups and Cohorts

  • clinically isolated syndrome
    • In this study the term clinically isolated syndrome (CIS) is defined according to the Task Force on Differential Diagnosis in MS, as a monophasic presentation of neurological symptoms with suspected underlying inflammatory demyelinating disease (Miller 2008).
  • remitting, relapsing MS
    • remitting relapsing MS according to the criteria by Poser (Poser 1983) or McDonald (McDonald 2001)

Clinical Trial Outcome Measures

Primary Measures

  • Multiple Sclerosis Inventory Cognition (MUSIC)
  • Annual Corpus Callosum Index decrease

Secondary Measures

  • Corpus callosum Index at baseline
  • Time to clinically definite MS
  • The Symbol Digit Modalities Test (SDMT)
  • Ratio treatment duration to disease duration

Participating in This Clinical Trial

Inclusion Criteria

  • Patients between 18 and 55 years at presentation – Diagnosis of relapsing-remitting MS according to revised McDonald criteria 2005, clinically isolated syndrome suggestive of MS – Patients treated with interferon-beta 1b – Untreated patients – EDSS under 5.5 Exclusion Criteria:

  • Brain pathology other than MS – Known history of head trauma – Pure spinal manifestation of demyelization – Neuromyelitis optica – Primary and secondary progressive MS – Benzodiazepine intake within the last three months – Relapse within the last three months – Steroid intake within the last three months – History of severe depressive disorder and/or suicidality, seizure, drug or alcohol abuse – No informed consent – Insufficient knowledge of German

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cantonal Hospital of St. Gallen
  • Collaborator
    • Bayer
  • Provider of Information About this Clinical Study
    • Murat Yildiz, Cantonal Hospital Saint Gallen
  • Overall Official(s)
    • Murat Yildiz, MD, Principal Investigator, Cantonal Hospital Saint Gallen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.